BioNTech reports positive lung cancer clinical trial data

BioNTech has presented promising clinical trial results for its cancer treatments at a lung cancer congress. Data from the Phase 3 PRESERVE-003 study regarding Gotistobart (BNT316/ONC-392) showed that patients with pretreated squamous non-small cell lung cancer (NSCLC) experienced a significant extension in median overall survival compared to those receiving the standard chemotherapy, Docetaxel.

Additionally, Phase 1/2 study data for a combination of Pumitamig and Elfetabart showed positive results for advanced small cell lung cancer. While some observers describe these findings as a potential breakthrough, researchers note that the studies are still in relatively early stages.

Financial analysts have responded positively to the data. UBS maintained a buy recommendation for BioNTech with a price target of $135.00. Berenberg raised its price target from $132.00 to $140.00 while maintaining a buy rating, and Jefferies also issued a buy recommendation with a target of $138.00.